|Mr. Christopher J. Moreau||CEO & Director||108k||N/A||1965|
|Mr. Michael S. M. Sadhra CA, CPA||CFO & Director||48k||N/A||1969|
|Mr. Mark Williams||Chief Science Officer||138.49k||N/A||N/A|
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of nonÂalcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Algernon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.